Silk biomaterials offer unique properties to medical products, improving their safety and efficacy. Serigen's co-founder Dr. Premnath explains these advantages of silk protein.
Serigen wins the prestigious Biotechnology Ignition Grant from DBT-BIRAC Serigen (previously BiolMed) has been selected for the prestigious Biotechnology Ignition Grant for its flagship product Serioss. Biotechnology Ignition grant is…
BIRAC awards SBIRI grant to Serigen Serigen (previously BiolMed)is the proud recipient of the Small Business Innovation Research Initiative (SBIRI) grant by Biotechnology Industry Research Assistance Council (BIRAC). BIRAC is…
Serigen receives the DBT-BIRAC-BIPP grant funding Serigen (previously BiolMed) has been selected for the Biotechnology Industry Partnership Program (BIPP) funding scheme. BIPP is implemented by Biotechnology Industry Research Assistance Council…
Serigen receives the DBT-BIRAC-SBIRI grant funding Serigen (previously BiolMed) has been awarded an Small Business Innovation Research Initiative (SBIRI) grant by Biotechnology Industry Research Assistance Council (BIRAC). BIRAC is an…
Serigen completes first round of angel investment Serigen has completed its first round of angel investment. The round will accelerate product development of Serioss, Serimat and Seriderm and contribute towards setting up of pilot…
Serigen receives the DBT-BIRAC-SBIRI grant funding Yet another feather in the cap! Serigen (previously BiolMed) receives a Small Business Innovation Research Initiative (SBIRI) grant by Biotechnology Industry Research Assistance Council…
Seed Funding Round Serigen, an innovative tissue regeneration startup, raises INR 5.8 crores from BioAngels, Colossa Ventures and other Angels Serigen Mediproducts is an innovative medical products company developing nextgen…
Serigen wins the Dr Keki Gharda Industrial Innovation Award by SPSI Serigen has been awarded the first Dr K.H. Gharda Industrial Innovation Award in Polymer Science by SPSI “For having…
Accomplished medical device professional. Over 25 years in leadership roles in New Product Development, Quality & Regulatory Affairs, Marketing, Sales and Business Development.Proven track record of managing new product development from concept to market. Hands-on expertise in Risk Management, Design Verification & Validation, Excellent problem-solving ability. Strong background of interaction with KOLs, customers and trade channels in India and EMEA. Ravi Sarangpani has completed his Production Engineering in 1989 from K.J Somaiya College of Engineering, Mumbai University.
Self Employed – 2019 onwards
Consulting and Advisory Services for medical device and healthcare companies and start-ups. Mentor at Venture Center, Asia’s largest science-based incubator and Materials Science Center, Indian Institute of Science, Bengaluru. Faculty at AIM-Prime, training & guidance program for deep tech startups, initiative of Atal Innovation Mission and Niti Aayog implemented by Venture Center, Pune.
Headed new product development for trauma, oncology and hip replacement for APAC region, 20-member team, USD 1m budget. Launched four new products in five years within budgets and targeted timelines. Implemented effective project management within a crossfunctional, multi-national, multi-locational project team. Developed and implemented design control procedure as per revised MDR that was adopted as model for implementation across sites.
Headed Design, Quality and Regulatory Functions. Implemented structured D&D methodology, cross functional teams, ‘first time right’ culture for execution efficiency. Started in-house design verification including computational modeling and testing. Implemented GD&T across team and manufacturing organization. Launched 3 new products that contributed to successful clinical outcomes for 15000+ patients between 2012 – 2018. Designed innovative locking plate system for fractures that was granted patents in U.S, EU, Japan.
Joined in start-up stage, grew business from $150k in 1993 to $3.6m by 2009. Established strong brand image and presence across India and 29 other countries. Developed KOL relationships that led to strong clinician driven product development.
